1 BTC
=
- USD
Perspective Therapeutics, Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About Perspective Therapeutics, Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Market Statistics
Trading Metrics
How to Buy CATX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy CATX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesPerspective Therapeutics announced it will present updated clinical data from all three of its radiopharmaceutical programs at the 2026 ASCO Annual Meeting. Key highlights include one new responder in the [212Pb]VMT01 melanoma monotherapy cohort (29% response rate), advancement of [212Pb]PSV359 to Cohort 3 with favorable safety profile, and continued deepening of responses in [212Pb]VMT-α-NET for neuroendocrine tumors. All programs demonstrated good tolerability with no dose-limiting toxicities reported.
The pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.
Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET, a first-in-class 212Pb-radiopharmaceutical targeting SSTR2-positive neuroendocrine tumors. The trial showed a 43% objective response rate in Cohort 2 patients, with no dose-limiting toxicities or serious treatment-related complications. The company plans to submit clinical evidence for regulatory engagement in 2026.
Perspective Therapeutics, a radiopharmaceutical development company, announced that its senior leadership will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, and the Piper Sandler Spring Biopharma Symposium on April 16, 2026. The company is developing advanced cancer treatments using alpha-emitting isotope 212Pb with complementary imaging diagnostics, with programs in Phase 1/2a trials for neuroendocrine tumors, melanoma, and solid tumors.
Several biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.
